Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109

A preparation of autologous T lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D) and the co-stimulatory domain 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109 specifically recognize and induce selective toxicity in GPRC5D-expressing tumor cells. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.
Synonym:autologous anti-GPRC5D CAR T cells MCARH109
autologous anti-GPRC5D CAR-T cells MCARH109
autologous GPRC5D-targeted CAR T cells MCARH109
Code name:MCARH 109
MCARH-109
MCARH109
Search NCI's Drug Dictionary